Reginald Gohh, MD
Nephrology · Riverside, RINPI 1063466282
Payments from drug & device makers
Across 216 payments — averaging $4923.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$466K
- United Therapeutics Corporation$415K
- Vertex$91K
- Veloxis Pharmaceuticals, Inc.$35K
- CSL Behring$32K
- Sanofi$11K
- plus $14K from 22 others
Across 9 payments — averaging $240.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Inc.$1K
- Accord Healthcare, Inc.$779
- Teva Pharmaceuticals USA, Inc.$84
- Apotex Inc.$52
What the payments were for
- Consulting fees$31,62267%
- Speaking & faculty fees$9222%
- Travel & lodging$10,24922%
- Food & beverage$4,51910%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 49 | $466,308 |
| United Therapeutics Corporation | 27 | $415,434 |
| Vertex | 8 | $90,580 |
| Veloxis Pharmaceuticals, Inc. | 50 | $34,581 |
| CSL Behring | 35 | $31,670 |
| Sanofi | 1 | $10,500 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,613 |
| Mallinckrodt Enterprises LLC | 3 | $2,166 |
| Ironwood Pharmaceuticals, Inc | 1 | $1,675 |
| Amneal Pharmaceuticals LLC | 2 | $1,375 |
| AstraZeneca(2 entities) | 12 | $994 |
| Hikma Pharmaceuticals USA | 4 | $937 |
| Aurobindo Pharma USA, Inc. | 1 | $875 |
| Akorn, Inc. | 1 | $500 |
| Zydus Pharmaceuticals (USA) Inc. | 1 | $375 |
| Mylan Inc. | 1 | $375 |
| Sanofi-aventis U.S. LLC | 3 | $325 |
| Otsuka America Pharmaceutical, Inc. | 3 | $303 |
| Eurofins Viracor, LLC | 1 | $168 |
| Calliditas Therapeutics US Inc. | 2 | $151 |
| Bayer | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $114 |
| Amgen | 1 | $104 |
| Accord Healthcare, Inc. | 1 | $102 |
| Sandoz | 2 | $58 |
| Novartis | 1 | $58 |
| Merck | 1 | $26 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$40,004
- Mycophenolate Mofetil$3,125
- ACTHAR$2,140
- MYCOPHENOLATE$875
- THYMOGLOBULIN$259
- LOKELMA$126
- TARPEYO$125
- JYNARQUE$125
- FARXIGA$118
- Kerendia$117
- LIVTENCITY$114
- Parsabiv$104
- Non-Product Related$102
- NULOJIX$101
How this compares
$1,063,496 in reported general payments places this provider in the 95th percentile of 45 nephrology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 27 | $21,618 |
| EliquisApixaban | 16 | $20,951 |
| Cinacalcet Hcl | 47 | $11,273 |
| JardianceEmpagliflozin | 11 | $6,327 |
| Mycophenolic AcidMycophenolate Sodium | 29 | $5,173 |
| Tacrolimus | 25 | $3,197 |
| Azathioprine | 12 | $2,151 |
| Mycophenolate Mofetil | 21 | $1,401 |
| Midodrine Hcl | 17 | $1,097 |
| Prednisone | 207 | $1,083 |
| Nifedipine ErNifedipine | 26 | $1,030 |
| Pantoprazole Sodium | 51 | $554 |
| Amlodipine Besylate | 49 | $497 |
| Lisinopril | 43 | $496 |
| Carvedilol | 47 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $994 | $21,61827 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $1,375 | $1,40121 claims |
| Mylan Inc.Atorvastatin Calcium | $375 | $39431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 nephrology providers in Rhode Island.
Other nephrology in Riverside
- Douglas SheminRiverside$1.2M
- Ankur ShahRiverside$328K
- Jie TangRiverside$173K
- George BaylissRiverside$117K
- Matthew LynchRiverside$53K
- Susie HuRiverside$40K
- Kristen TillquistRiverside$2K
- Basma MerhiRiverside$2K
- John ObellRiverside$2K
- Sandipan ShringiRiverside$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.